SUBSCRIBE
SUBSCRIBE
News   Drug Development

Kamada Ltd. was Granted New Orphan Drug Designation by the FDA, for its Aerosolized AAT for the Treatment of Bronchiectasis

April 8, 2008 | 
1 min read
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE: KMDA), a biopharmaceutical company which develops, manufactures and markets specialty life-saving therapeutics, announces today that the company was granted an Orphan Drug Designation to its Aerosolized Alpha-1 Antitrypsin (AAT) product to treat Bronchiectasis.
Clinical research Phase II Asia
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
 · 
8 min read
 · 
Tristan Manalac
businessman Climbing mountain. Symbol of success, career, leadership and goal
Immuno-oncology
Four Therapies Hanging On in Troubled TIGIT Space
July 7, 2025
 · 
9 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
July 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Painful female periods concept. Vector flat character illustration. Woman standing and suffering menstrual abdominal pain isolated on pink background. Design for health care.
Women’s Health
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain
July 2, 2025
 · 
1 min read
 · 
Annalee Armstrong